II.studio / Shutterstock.com
9 September 2019Big PharmaSarah Morgan
Novartis and BenevolentAI sign AI oncology deal
Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
2 May 2019 AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.
Asia
10 October 2019 Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Editor's picks
Editor's picks
Big Pharma
2 May 2019 AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.
Asia
10 October 2019 Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Big Pharma
2 May 2019 AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.
Asia
10 October 2019 Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Big Pharma
10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.